- Home
- MIRM vs FICO Comparison
MIRM vs FICO Comparison
Compare MIRM & FICO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- FICO
- Stock Information
- Founded
- MIRM 2018
- FICO 1956
- Country
- MIRM United States
- FICO United States
- Employees
- MIRM N/A
- FICO N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- FICO Business Services
- Sector
- MIRM Health Care
- FICO Consumer Discretionary
- Exchange
- MIRM Nasdaq
- FICO Nasdaq
- Market Cap
- MIRM 3.3B
- FICO 32.2B
- IPO Year
- MIRM 2019
- FICO 1987
- Fundamental
- Price
- MIRM $73.50
- FICO $1,515.00
- Analyst Decision
- MIRM Strong Buy
- FICO Buy
- Analyst Count
- MIRM 10
- FICO 12
- Target Price
- MIRM $74.20
- FICO $2,068.67
- AVG Volume (30 Days)
- MIRM 679.0K
- FICO 308.9K
- Earning Date
- MIRM 11-11-2025
- FICO 11-05-2025
- Dividend Yield
- MIRM N/A
- FICO N/A
- EPS Growth
- MIRM N/A
- FICO 34.32
- EPS
- MIRM N/A
- FICO 25.55
- Revenue
- MIRM $429,161,000.00
- FICO $1,928,927,000.00
- Revenue This Year
- MIRM $53.08
- FICO $18.02
- Revenue Next Year
- MIRM $20.45
- FICO $13.91
- P/E Ratio
- MIRM N/A
- FICO $60.72
- Revenue Growth
- MIRM 62.33
- FICO 16.66
- 52 Week Low
- MIRM $36.86
- FICO $1,300.00
- 52 Week High
- MIRM $78.10
- FICO $2,402.52
- Technical
- Relative Strength Index (RSI)
- MIRM 59.29
- FICO 52.71
- Support Level
- MIRM $73.35
- FICO $1,511.04
- Resistance Level
- MIRM $74.99
- FICO $1,602.92
- Average True Range (ATR)
- MIRM 2.34
- FICO 41.07
- MACD
- MIRM -0.98
- FICO 4.57
- Stochastic Oscillator
- MIRM 24.58
- FICO 31.22
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About FICO Fair Isaac Corproation
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.